We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, N.I.H., EXTRAMURAL
RESEARCH SUPPORT, NON-U.S. GOV'T
Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast.
Breast Cancer Research and Treatment 2008 October
BACKGROUND: The diagnosis of ductal carcinoma in situ (DCIS) has become increasingly common, but it is not clear which factors predict the development of subsequent breast cancers in these women. The risk of second primary breast tumors was examined in a large, ethnically diverse population-based cohort of women with DCIS. METHODS; California Cancer Registry data on 23,547 women with first DCIS diagnosed in 1988-1999 were examined to estimate the incidence of second DCIS and invasive breast cancer relative to women in the general population. Relative risks were calculated using Poisson regression to estimate which women with DCIS were likely to develop a second DCIS or invasive breast cancer.
RESULTS: Compared to the general population, women with DCIS had significantly increased risk of contralateral DCIS (standardized incidence ratio [SIR] 4.2, 95% confidence interval [CI] 3.7-4.7), contralateral invasive cancer (SIR 1.4, 95% CI 1.2-1.5), ipsilateral DCIS (SIR 4.2, 95% CI 3.5-5.0), and ipsilateral invasive cancer (SIR 1.7, 95% CI 1.4-2.1). Variation by race/ethnicity, age, time, and tumor and treatment characteristics were observed. Black women were 1.9-fold more likely to develop ipsilateral invasive cancer than white women. Young age at onset, comedo histology and having received partial mastectomy only or having neither surgical nor radiation treatment for first DCIS were predictive of ipsilateral cancers.
CONCLUSIONS: Close follow-up of women with DCIS is warranted, particularly those who are Black or diagnosed at young age. Investigations should continue to clarify the underlying mechanisms of racial, age, and other differences in second cancer risk.
RESULTS: Compared to the general population, women with DCIS had significantly increased risk of contralateral DCIS (standardized incidence ratio [SIR] 4.2, 95% confidence interval [CI] 3.7-4.7), contralateral invasive cancer (SIR 1.4, 95% CI 1.2-1.5), ipsilateral DCIS (SIR 4.2, 95% CI 3.5-5.0), and ipsilateral invasive cancer (SIR 1.7, 95% CI 1.4-2.1). Variation by race/ethnicity, age, time, and tumor and treatment characteristics were observed. Black women were 1.9-fold more likely to develop ipsilateral invasive cancer than white women. Young age at onset, comedo histology and having received partial mastectomy only or having neither surgical nor radiation treatment for first DCIS were predictive of ipsilateral cancers.
CONCLUSIONS: Close follow-up of women with DCIS is warranted, particularly those who are Black or diagnosed at young age. Investigations should continue to clarify the underlying mechanisms of racial, age, and other differences in second cancer risk.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app